Skip to content
OpenCapital
Get started

BioLife Solutions BLFS Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number at other companies

STERIS logo
STERISSTE
——

Other financials

Income statement

See full
Revenue$27.5M+24.7%
Gross profit$17.5M+18.2%
Operating income$27.0K+105%
Net income$1.2M+365%
EPS (diluted)$0.02—

Balance sheet

See full
Cash & equivalents$22.8M-65.9%
Total debt$17.4M-35.6%
Total equity$372.2M+5.6%
Total assets$400.9M+1.5%

Cash flow

See full
Operating cash flow-$491.0K-128%
CapEx$167.0K-4.6%
Free cash flow-$658.0K-142%

Valuation

See full
Market cap$1.34B+33.1%
Enterprise value$1.34B+38.1%
P/S13.5×+0.6×

Profitability

See full
Gross margin66.9%—
Operating margin-16.7%—
Net margin-68.7%—
FCF margin-15.9%+18.7pp

Returns & leverage

See full
Return on equity-14.5%-4.7pp
Debt / equity0×0.0×
Current ratio7.3×+2.6×

Where this comes from

Reported directly by BioLife Solutions in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.

The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioLife Solutions's share based compensation arrangement by share based payment award options exercisable number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioLife Solutions's share based compensation arrangement by share based payment award options exercisable number?
BioLife Solutions (BLFS) reported share based compensation arrangement by share based payment award options exercisable number of $17K in Q1 2026.
How has BioLife Solutions's share based compensation arrangement by share based payment award options exercisable number changed year-over-year?
BioLife Solutions's share based compensation arrangement by share based payment award options exercisable number decreased by 86.6% year-over-year, from $127K to $17K.